Q3 2018 Earnings Forecast for OptimizeRx Co. Issued By B. Riley (OPRX)

OptimizeRx Co. (OTCMKTS:OPRX) – Equities research analysts at B. Riley lowered their Q3 2018 EPS estimates for shares of OptimizeRx in a research report issued to clients and investors on Wednesday, August 8th. B. Riley analyst A. D’silva now expects that the technology company will post earnings of $0.00 per share for the quarter, down from their prior estimate of $0.02. B. Riley has a “Buy” rating and a $17.00 price target on the stock. B. Riley also issued estimates for OptimizeRx’s FY2020 earnings at $0.44 EPS.

OptimizeRx (OTCMKTS:OPRX) last issued its quarterly earnings results on Tuesday, August 7th. The technology company reported $0.02 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.02. OptimizeRx had a negative return on equity of 22.08% and a negative net margin of 10.02%. The firm had revenue of $5.10 million during the quarter, compared to the consensus estimate of $4.34 million.

Other equities research analysts also recently issued research reports about the company. Lake Street Capital raised their target price on OptimizeRx to $12.00 and gave the company a “positive” rating in a report on Monday, June 25th. Roth Capital reissued a “buy” rating on shares of OptimizeRx in a report on Monday, June 18th.

Shares of OptimizeRx opened at $12.04 on Friday, according to Marketbeat Ratings. OptimizeRx has a 1-year low of $2.30 and a 1-year high of $12.10. The firm has a market cap of $120.07 million, a P/E ratio of -57.33 and a beta of 0.53.

A hedge fund recently bought a new stake in OptimizeRx stock. Perkins Capital Management Inc. purchased a new stake in OptimizeRx Co. (OTCMKTS:OPRX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 157,118 shares of the technology company’s stock, valued at approximately $1,634,000. OptimizeRx accounts for 1.2% of Perkins Capital Management Inc.’s holdings, making the stock its 25th biggest position. Perkins Capital Management Inc. owned approximately 1.36% of OptimizeRx at the end of the most recent quarter. 0.35% of the stock is owned by hedge funds and other institutional investors.

In related news, President Miriam J. Paramore acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 15th. The stock was purchased at an average price of $8.07 per share, for a total transaction of $40,350.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders have purchased 7,995 shares of company stock valued at $71,691.

About OptimizeRx

OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.

See Also: Growth Stocks

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply